Literature DB >> 10086776

A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura.

M N Warner1, J C Moore, T E Warkentin, A V Santos, J G Kelton.   

Abstract

Idiopathic thrombocytopenic purpura (ITP) is a disorder in which platelets, sensitized by autoantibodies, are destroyed by the reticuloendothelial system. The diagnosis of ITP has been a clinical one because assays measuring platelet-associated IgG (PAIgG) have low specificity. The recently introduced assays that measure antibodies against specific platelet glycoproteins (GP) offer the possibility of improved specificity. In this report we describe two prospective studies. In the first study we compared two protein-specific assays (AC and MAIPA) looking for the presence of autoantibodies against GP IIb/IIIa in 81 patient samples. These results were compared with an immunoradiometric assay for PAIgG. The second study investigated the enhanced sensitivity of measuring anti-GP Ib/IX autoantibodies in 76 patient samples. The protein-specific assays were able to differentiate immune from non-immune thrombocytopenia (specificity 91%, sensitivity 39%), whereas the PAIgG assay could not (specificity 19%, sensitivity 78%). The addition of the Ib/IX AC assay maintained a specificity of 92% while increasing the diagnostic sensitivity to 66%. In contrast to the PAIgG assay, there was no correlation between the platelet count and the likelihood or degree of positivity within the control samples using the glycoprotein assays. These studies confirm that glycoprotein assays can be used as diagnostic tests for ITP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086776     DOI: 10.1046/j.1365-2141.1999.01218.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  28 in total

Review 1.  Laboratory testing for heparin-induced thrombocytopenia.

Authors:  T E Warkentin
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 2.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

Review 3.  Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.

Authors:  Lisa J Toltl; Donald M Arnold
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

4.  Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure.

Authors:  Samo Zver; Irena Preloznik Zupan; Peter Cernelc
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

5.  Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia.

Authors:  Sabrina Shrestha; Ishac Nazy; James W Smith; John G Kelton; Donald M Arnold
Journal:  Blood Adv       Date:  2020-07-14

6.  CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

Authors:  Li Ma; Elisa Simpson; June Li; Min Xuan; Miao Xu; Laura Baker; Yan Shi; Issaka Yougbaré; Xiaozhong Wang; Guangheng Zhu; Pingguo Chen; Gerald J Prud'homme; Alan H Lazarus; John Freedman; Heyu Ni
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

Review 7.  Autoimmune complications in chronic lymphocytic leukaemia (CLL).

Authors:  Clive S Zent; Neil E Kay
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

8.  A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia.

Authors:  Vishwanath K Mahabir; Catherine Ross; Snezana Popovic; Mona Lisa Sur; Jacqueline Bourgeois; Wendy Lim; James N George; Grace Wang; Richard J Cook; Lisa J Toltl; Ishac Nazi; John G Kelton; Donald M Arnold
Journal:  Eur J Haematol       Date:  2012-12-13       Impact factor: 2.997

9.  Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia.

Authors:  D M Arnold; S Santoso; A Greinacher
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

10.  Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.

Authors:  Bahareh Ghadaki; Ishac Nazi; John G Kelton; Donald M Arnold
Journal:  Transfusion       Date:  2013-03-03       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.